Boston Scientific Corporation (BSX) , despite industrywide macroeconomic upheavals,  has been seeing strong growth momentum across its target markets. Earlier this month, the company posted robust fourth-quarter 2024 results, surpassing market expectations and setting a positive outlook for 2025. These have led to upward revisions in analyst estimates.The Zacks Consensus Estimate for first-quarter 2025 earnings per share has been revised upward by 3 cents over the past 60 days, with six analysts upgrading t ...

Financial Performance - In 2024, Boston Scientific's net sales reached $16.747 billion, a 17.6% increase from $14.240 billion in 2023, driven by operational net sales growth of 18.5%[184] - The reported net income attributable to common stockholders in 2024 was $1.853 billion, or $1.25 per diluted share, compared to $1.570 billion, or $1.07 per diluted share in 2023[184] - Total net sales increased to $16.747 billion in 2024 from $14.240 billion in 2023, representing a growth of 17.6%, with operational growth of 13.1% and an 80 basis point negative impact from foreign currency fluctuations[202][203] Business Segments - The Endoscopy business generated net sales of $2.687 billion in 2024, representing 16% of consolidated net sales, with an 8.3% increase from 2023[189] - Urology products net sales were $2.200 billion in 2024, accounting for 13% of consolidated net sales, reflecting a 12.0% increase compared to 2023[191] - Neuromodulation products net sales reached $1.106 billion in 2024, a 13.3% increase from 2023, representing 7% of consolidated net sales[193] - Cardiology products net sales were $8.344 billion in 2024, a 24.4% increase from 2023, making up 50% of consolidated net sales[195] - Peripheral Interventions net sales totaled $2.410 billion in 2024, a 14.2% increase from 2023, representing 14% of consolidated net sales[197] Growth and Acquisitions - The company experienced organic net sales growth of 16.4% in 2024, with acquisitions contributing an additional 210 basis points[184] - The acquisition of Axonics in Q4 2024 positively impacted Urology's organic net sales growth by 330 basis points[191] - Boston Scientific aims to expand its global presence, particularly in Emerging Markets, to drive net sales and market share growth[199] - Emerging Markets net sales accounted for 16% of consolidated net sales in both 2024 and 2023, with a growth of 16.1% in 2024 driven by operational growth of 19.6% despite a 360 basis point negative impact from foreign currency fluctuations[200] Expenses and Profitability - Gross profit for 2024 was $11.490 billion, with a gross profit margin of 68.6%, down from 69.5% in 2023, primarily due to inventory charges and strategic manufacturing capacity investments[204][205] - Selling, General and Administrative (SG&A) expenses rose to $5.984 billion in 2024, a 15% increase from 2023, while as a percentage of net sales, it decreased by 70 basis points[209] - Research and Development (R&D) expenses increased to $1.615 billion in 2024, a 14% rise compared to 2023, reflecting the company's commitment to advancing medical technologies[211] Debt and Financing - Total debt as of December 31, 2024, was $10.746 billion, an increase from $9.102 billion in 2023, with current debt obligations rising to $1.778 billion[242] - Cash used for investing activities in 2024 was $(5.687) billion, primarily for acquisitions including Axonics and Silk Road Medical[235] - Cash provided by financing activities included $2.145 billion from the Eurobonds offering, used to fund the Axonics acquisition and repay senior notes[236] Tax and Compliance - The reported tax rate for 2024 was 19.1%, down from 19.8% in 2023, with a rate from continuing operations of 18.0%[222] - The company expects the impact of the Pillar Two global minimum tax on its 2024 tax rate to be immaterial, with similar expectations for 2025[226] - The company expects to incur significant expenditures related to compliance with the EU MDR regulatory requirements, which are not considered ordinary course expenditures[285] Restructuring and Future Plans - The company recorded restructuring charges of $16 million and restructuring-related charges of $212 million in 2024 as part of its global restructuring program[217] - The 2023 Restructuring Plan is estimated to incur total pre-tax charges of approximately $450 million to $550 million, with cash outlays expected to be between $350 million and $450 million[251] - The restructuring plan aims to reduce gross annual pre-tax expenses by approximately $225 million to $275 million as benefits are realized[251] Legal and Regulatory Matters - The company is involved in various legal and regulatory proceedings, which may require significant expenditures or impact product sales[272] - Anticipated costs of settlement and damages for product liability claims are accrued based on historical experience, with significant judgment required in estimating these accruals[272] Internal Controls and Risk Management - The company's internal control over financial reporting was assessed as effective as of December 31, 2024[289] - The independent auditor expressed an unqualified opinion on the effectiveness of the company's internal control over financial reporting[294] - The company uses a risk management program that includes derivative financial instruments to address market risks from changes in currency exchange rates and interest rates[303]

Boston Scientific (BSX) is gaining from new product launches and accretive acquisitions. Yet, unfavorable currency movement and macroeconomic concerns are major dampeners. The stock carries a Zacks Rank #3 (Hold).Factors Driving BSX SharesBoston Scientific’s Endoscopy business within MedSurg is witnessing strong growth in endoluminal surgery and single-use imaging franchises, along with sustained growth of the AXIOS platform, where the company is reinvesting to drive expanded indications. It recently receiv ...

POLAND - 2024/11/21: In this photo illustration, the Boston Scientific company logo is seen ... [+] displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesBoston Scientific stock (NYSE: BSX) has gained 3% in the five days since its Q4 earnings report last week. Although the company exceeded expectations with both its results and guidance, the modest stock increase may be due to the significant price appreciation ah ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, February 10th:Boston Scientific Corporation (BSX) : This medical devices company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.2% over the last 60 days.Boston Scientific’s shares gained 19.3% over the last three months compared with the S&P 500’s advance of 0.4%. The company possesses a Momentum Score  of A.Enova International, Inc. (ENVA) : Thi ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Peoples Financial Services Corp. (PFIS) : This bank holding company for Peoples Security Bank and Trust Company has seen the Zacks Consensus Estimate for its current year earnings increasing 10.2% over the last 60 days.Boston Scientific Corporation (BSX) : This medical devices company has seen the Zacks Consensus Estimate for its current year earnings increasing 5.2% over the last 60 days.Enova International, Inc. (ENVA) : This technolo ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Boston Scientific (BSX) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Boston Scientific is one of 1012 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is ...

Financial Data and Key Metrics Changes - In Q4 2024, operational sales grew 23% and organic sales grew 20%, exceeding the guidance range of 14% to 16% [10] - Full year 2024 operational sales grew 18.5% while organic sales grew 16%, surpassing the guidance of approximately 15% [10] - Q4 adjusted EPS was $0.70, a 26% increase, exceeding the guidance range of $0.64 to $0.66 [11] - Full year adjusted EPS was $2.51, a 22% increase, exceeding the guidance range of $2.40 to $2.47 [11] - Adjusted operating margin for full year 2024 was 27%, an increase of 70 basis points [12] Business Line Data and Key Metrics Changes - Urology grew 8% in Q4 and 9% for the full year, with operational growth of 20% in Q4 [17] - Endoscopy sales grew 8% operationally and 7% organically in Q4, with full year growth of 9% operationally [20] - Cardiology sales grew 32% in Q4 and 25% for the full year, with interventional cardiology therapies growing 10% in Q4 [23] - Electrophysiology sales grew 172% in Q4 and 139% for the full year, driven by FerraPulse [29] Market Data and Key Metrics Changes - U.S. operational growth was 31% in Q4 and 21% for the full year [14] - Asia Pacific grew 12% operationally in Q4 and 16% for the full year, with strong performance in Japan and China [15] - Middle East, Europe, and Africa grew 12% in Q4 and 14% for the full year [14] Company Strategy and Development Direction - The company aims to continue outpacing market growth in 2025, with expectations of organic growth of 14% to 16% [12] - Focus on innovation and execution across global business units, with significant investments in product development [10] - Strategic acquisitions, such as Bolt Medical and Intera Oncology, are expected to enhance the product portfolio [12][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining strong growth momentum despite potential competition in the PFA market [75] - Anticipated challenges in China due to VBP pricing pressures, but still expect mid-teens growth [17] - Management remains focused on driving differentiated results and enhancing the company culture [36] Other Important Information - Free cash flow for Q4 was $1.181 billion, with full year free cash flow of $2.648 billion, achieving 71% conversion [43] - The company has a cash reserve of $414 million and a gross debt leverage ratio of 2.2 times [44] - Guidance for 2025 includes reported revenue growth of 12.5% to 14.5% and organic growth of 10% to 12% [45] Q&A Session Summary Question: Thoughts on PFA and Watchmen growth - Management noted excellent momentum in both FerraPulse and Watchmen, with a slight uptick in Watchmen growth due to reimbursement changes [60] Question: Long-term growth expectations - Management indicated a goal to outgrow market growth rates and maintain double-digit EPS growth despite potential tax rate increases [68] Question: Risks and upside in guidance - Management acknowledged potential competition in the PFA market but emphasized strong momentum across various regions and product lines [75] Question: Margin management and cash flow - Management discussed strategies for operating margin expansion and maintaining a focus on high-quality M&A as a primary use of cash [85] Question: Update on TAVR franchise - Management stated that discussions regarding the U.S. TAVR franchise are ongoing, with strong performance in Europe despite some impacts from U.S. trials [123] Question: Mapping strategy and market share - Management confirmed an open platform strategy for mapping, with a focus on enhancing the OPAL platform while supporting competitive systems [126]

Boston Scientific Corporation (BSX) posted fourth-quarter 2024 adjusted earnings per share (EPS) of 70 cents, up 27.3% from the year-ago figure. The figure beat the Zacks Consensus Estimate by 7.7% and also exceeded the company’s adjusted earnings per share guidance range of 64-66 cents per share.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The quarter’s adjustments included certain amortization expenses, acquisition/divestitures-related net charges, and restructuring and restructu ...